FDAsafety guidance72% confidence
Submitting Clinical Trial Datasets to Evaluate the Impact of Immunogenicity on the Pharmacokinetics of Drug
Source: FDA
Why This Matters
Why this matters: illustrates how regulators handled a comparable safety guidance decision relevant to Boehringer Ingelheim.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Metabolic Disorders · Oral Therapy
- Sub-indication
- General
Related signal: Boehringer Ingelheim's BI 764198 Trial Focuses on Safety and Pharmacokinetics